Evidence map›Paper›PMID 29671197›Full record

ArticleJournal of neuro-oncology2018

Distinct response to GDF15 knockdown in pediatric and adult glioblastoma cell lines.

Mirella Baroni, Suely Kazue Nagahashi Marie, Paola Fernanda Fedatto, Augusto Faria Andrade, Veridiana Kill Suazo, Gustavo Alencastro Veiga Cruzeiro, Rosane de Paula Queiroz, Luiz Gonzaga Tone, Carlos Alberto Scrideli

Open access · greenAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mirella BaroniDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Suely Kazue Nagahashi MarieDepartment of Neurology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Paola Fernanda FedattoDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Augusto Faria AndradeDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Veridiana Kill SuazoDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Gustavo Alencastro Veiga CruzeiroDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Rosane de Paula QueirozDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Luiz Gonzaga ToneDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Carlos Alberto ScrideliDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. scrideli@fmrp.usp.br.ORCID http://orcid.org/0000-0001-6618-789X
Universidade de São Paulo · BRUniversidade de Ribeirão Preto · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 307965/2014-7Fundação de Amparo à Pesquisa do Estado de São Paulo 2012/11315-6
6 · The paper itself

Abstract

introductionGlioblastoma (GBM) is the most common malignant primary brain tumor affecting adults. In pediatric patients, GBM exhibits genetic variations distinct from those identified in the adult GBM phenotype. This tumor exhibits complex genetic changes leading to malignant progression and resistance to standard therapies including radiotherapy and temozolomide treatment. The GDF15 gene codes for a growth factor whose expression is altered in the presence of inflammations and malignancies. GDF15 is associated with a poor prognosis and with radio- and chemoresistance in a variety of tumors. The aim of this study was to compare the response to GDF15 knockdown in adult (U343) and pediatric (KNS42) GBM cell line models.

methodsThe expression of the GDF15 gene was investigated by qRT-PCR and overexpression was identified in both GBM cell lines. The KNS42 and U343 cell lines were submitted to lentiviral transduction with shRNA of GDF15 and validated at the protein level. To understand the difference between cell lines, RNAseq was performed after GDF15 knockdown.

resultsThe data obtained demonstrated that the pathways were differentially expressed in adult GBM and pediatric GBM cell lines. This was confirmed by functional assays perfomed after independent treatments (radiotherapy and TMZ).

conclusionThese results demonstrated that GBM cell lines had distinct responses to GDF15 knockdown, a fact that can be explained by the different molecular profile of pediatric and adult GBM.

Indexed as

AdultAntineoplastic Agents, AlkylatingApoptosisCell Line, TumorCell ProliferationChildGene Expression Regulation, NeoplasticGene Knockdown TechniquesGlioblastomaGrowth Differentiation Factor 15HumansRadiotherapyRNA, Small InterferingTemozolomideAntineoplastic Agents, AlkylatingGDF15 protein, humanGrowth Differentiation Factor 15RNA, Small InterferingTemozolomideGDF15GlioblastomaRadiotherapyRNAseqShRNATemozolomide

Identifiers

PMID29671197
OpenAlexW2802440867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.